Monique C. Tavares
Sao Paulo, SP, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort.
Journal: NPJ breast cancer
Published: February 20, 2026
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.
Journal: Breast cancer research and treatment
Published: November 22, 2025
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.
Journal: NPJ breast cancer
Published: November 02, 2025
Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.
Journal: Breast cancer research and treatment
Published: August 11, 2025
MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients.
Journal: The British journal of radiology
Published: May 09, 2025
MRI Response to Neoadjuvant Chemotherapy and Prognostic Implications in Breast Cancer Patients.
Journal: The British journal of radiology
Published: May 09, 2025
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.
Journal: Breast (Edinburgh, Scotland)
Published: January 15, 2025
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.
Journal: Breast cancer research and treatment
Published: November 12, 2024
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer.
Journal: NPJ breast cancer
Published: March 20, 2024
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population.
Journal: Oncology and therapy
Published: February 29, 2024
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
Journal: Breast cancer research and treatment
Published: April 17, 2021
A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Journal: BMC cancer
Published: March 31, 2021
Last Updated: 09/26/2026